Shots VCNDD and BI enters into two agreement for the development and commercialization of two small molecules targeting GPCRs for neuropsychiatric disorders The focus of the agreement is to develop […]readmore
Tags : Boehringer Ingelheim
Shots: Domain to receive upfront, milestones, and royalties on sales from Boehringer Ingelheim The focus of the agreement is to discover & develop GPCRs, using Domain’s DTect-All and bioSens-All technology […]readmore
Shots: Lily and BI reports results of EMPA-REG OUTCOME trial assessing Jardiance (10/25 mg qd) vs PBO, from 42 countries in 7,020 patients with T2D at high risk for cardiovascular […]readmore
Shots: The total acquisition value is based on option and share agreement i.e. EUR 210M signed in 2016 b/w two companies. Under the deal ViraTherapeutics will operate in Innsbruck, Austria […]readmore